Rosetta Genomics Receives Nasdaq Non-Compliance Letter

Nov 30, 2017

|

NEW YORK (GenomeWeb) – Rosetta Genomics said today that it has received notification that it is no longer in compliance with the Nasdaq's $1 minimum bid price requirement for continued listing.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Boosting Viral Surveillance

The Financial Times reports the US bolstering its ability to track SARS-CoV-2 alterations.

California Strain

The New York Times reports that Cedars-Sinai researchers have uncovered a new strain of SARS-CoV-2 in Southern California.

Nucleic Acids Research Studies on Pan-Cancer MiRNA Biogenesis Mutations, Skeletal Methylation, More

In Nucleic Acids Research this week: pan-cancer atlas focus on miRNA biogenesis mutations, methylation analysis of pig skeletal muscles, and more.

Lander Nominated for Science Advisor

President-elect Joe Biden has nominated Eric Lander to serve as director of the Office of Science and Technology Policy, the Associated Press says.

Featured White Papers

User-focused Product Definition for IVD Market Success

Lessons on Sample Accessioning and Processing at Clinical Labs During a Pandemic

Accelerating the Future of SARS-CoV-2 Testing

NGS-Based Target Capture for SARS-CoV-2 Detection and Characterization

Feb

11

Featured Webinar

Virtual Molecular Tumor Board Series: HRD and DNA Damage Repair

In this session, the first in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling has identified biomarkers related to homologous recombination deficiency and DNA damage repair.

Feb

17

Featured Webinar

Single-Cell Multiomics Resolves a Sharp Disease-State Shift between Mild and Moderate COVID-19

Host immune responses play a central role in controlling SARS-CoV-2 infection, but they remain incompletely characterized and understood.

Feb

18

Featured Webinar

Single-Cell Multiomics to Elucidate Immune Alterations in the Human Tumor Microenvironment

The composition of the immune infiltrate in the human tumor microenvironment is a critical determinant of disease progression.

Feb

23

Featured Webinar

After the Surge: Driving Sample Processing Efficiency of Coronavirus Samples

As the world continues to contend with coronavirus and a surge in the infection rate, labs are required to run more samples than ever before.

Menu

Rosetta Genomics Receives Nasdaq Non-Compliance Letter

To read the full story....

Breaking News

Illumina Wins UK Patent Infringement Suit Against BGI, Affiliates

Oncocyte to Raise $25M in Stock Sale to Institutional Investors

Invitae to Raise $400M in Proposed Public Offering

Natera Sues Inivata, Alleging Infringement of Cancer Testing Patents

Cellink to Distribute Phasefocus High-Content Cell Imaging Platform

Biotheranostics' Breast Cancer Index Included in Latest NCCN Guidelines

The Scan

Boosting Viral Surveillance

California Strain

Nucleic Acids Research Studies on Pan-Cancer MiRNA Biogenesis Mutations, Skeletal Methylation, More

Lander Nominated for Science Advisor

Featured White Papers

Virtual Molecular Tumor Board Series: HRD and DNA Damage Repair

Single-Cell Multiomics Resolves a Sharp Disease-State Shift between Mild and Moderate COVID-19

Single-Cell Multiomics to Elucidate Immune Alterations in the Human Tumor Microenvironment

After the Surge: Driving Sample Processing Efficiency of Coronavirus Samples

What's Popular?

Natera Sues Inivata, Alleging Infringement of Cancer Testing Patents

CMS Finalizes Blood-Based Colon Cancer Screening NCD with Non-Coverage for Epi ProColon

Thermo Fisher Scientific to Acquire Mesa Biotech for Up to $550M

Jonathan Rothberg-Led Startup Looks to Bring Disposable POC SARS-CoV-2 Test to Market

Lucira Health Files for $115M IPO

Sponsorships